Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from The Five-Decade Journey of Small Cell Lung Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Small-cell lung cancer
10.1038/s41572-020-00235-0 · 2021 · External reference
10.3322/caac.21785
10.3322/caac.21785 · External reference
Cancer statistics, 2025
2025 · External reference
10.1038/s41571-024-00914-x
10.1038/s41571-024-00914-x · External reference
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
10.1038/s41591-024-03352-5 · 2025 · External reference
Unresolved reference
External reference
SCLC: Epidemiology, risk factors, genetic susceptibility, molecular pathology, screening, and early detection
10.1016/j.jtho.2022.10.002 · 2022 · External reference
The changing landscape of small cell lung cancer
10.1002/cncr.35281 · 2024 · External reference
Trends in the epidemiology of small-cell lung cancer: A Dutch nationwide population-based study over 1989-2020
10.1016/j.ejca.2023.112985 · 2023 · External reference
Small cell lung cancer (SCLC) incidence and trends vary by gender, geography, age, and subcategory based on population and hospital cancer registries in Hebei, China (2008-2017)
10.1111/1759-7714.13412 · 2020 · External reference
Comparative analysis of cancer statistics in China and the United States in 2024
10.1097/cm9.0000000000003442 · 2024 · External reference
Unresolved reference
External reference
10.1158/2159-8290.cd-22-0620
10.1158/2159-8290.cd-22-0620 · External reference
Racial and other healthcare disparities in patients with extensive-stage SCLC
2020 · External reference
Ethnic disparities in lung cancer incidence and differences in diagnostic characteristics: A population-based cohort study in England
10.1016/j.lanepe.2024.101124 · 2024 · External reference
10.1038/nature14664
10.1038/nature14664 · External reference
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies
10.1126/scitranslmed.abc7488 · 2021 · External reference
10.1158/2159-8290.cd-25-0375
10.1158/2159-8290.cd-25-0375 · External reference
AI-powered fragmentomics of cell-free DNA for early detection of multiple cancers
10.1038/s41591-025-03810-8 · 2025 · External reference
10.1038/s41586-025-09503-z
10.1038/s41586-025-09503-z · External reference
Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung
10.1016/j.ccr.2011.04.019 · 2011 · External reference
10.1101/gad.314815.118
10.1101/gad.314815.118 · External reference
10.1038/s41568-019-0133-9
10.1038/s41568-019-0133-9 · External reference
10.1158/2159-8290.cd-20-1863
10.1158/2159-8290.cd-20-1863 · External reference
A new floating cell line derived from human pulmonary carcinoma of oat cell type
1971 · External reference
10.1038/nprot.2016.097
10.1038/nprot.2016.097 · External reference
Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer
10.1038/nm.4239 · 2016 · External reference
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model
10.1016/s1535-6108(03)00220-4 · 2003 · External reference
10.1073/pnas.1821745116
10.1073/pnas.1821745116 · External reference
Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma
10.1158/0008-5472.can-09-4228 · 2010 · External reference
Crebbp loss drives small cell lung cancer and increases sensitivity to HDAC inhibition
10.1158/2159-8290.cd-18-0385 · 2018 · External reference
A multiplexed in vivo approach to identify driver genes in small cell lung cancer
10.1016/j.celrep.2023.111990 · 2023 · External reference
Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers
10.1038/s41392-025-02378-6 · 2025 · External reference
10.1038/s41573-025-01143-2
10.1038/s41573-025-01143-2 · External reference
10.1158/2159-8290.cd-21-0441
10.1158/2159-8290.cd-21-0441 · External reference
10.1016/j.ccell.2016.12.005
10.1016/j.ccell.2016.12.005 · External reference
10.1158/2159-8290.cd-22-0796
10.1158/2159-8290.cd-22-0796 · External reference
10.1158/2159-8290.cd-23-0656
10.1158/2159-8290.cd-23-0656 · External reference
DLL3 regulates Notch signaling in small cell lung cancer
10.1016/j.isci.2022.105603 · 2022 · External reference
10.1038/s41580-025-00835-2
10.1038/s41580-025-00835-2 · External reference
YAP drives fate conversion and chemoresistance of small cell lung cancer
10.1126/sciadv.abg1850 · 2021 · External reference
Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer
10.1038/s41421-024-00703-x · 2024 · External reference
10.1101/gad.328336.119
10.1101/gad.328336.119 · External reference
10.1038/nature22323
10.1038/nature22323 · External reference
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING
10.1172/jci185423 · 2025 · External reference
10.1016/j.cell.2023.12.004
10.1016/j.cell.2023.12.004 · External reference
Epigenetic landscape of small cell lung cancer: Small image of a giant recalcitrant disease
10.1016/j.semcancer.2020.11.006 · 2020 · External reference
10.1158/2159-8290.cd-24-0718
10.1158/2159-8290.cd-24-0718 · External reference
Regulation of neuronal invasion of small cell lung cancer by STMN2/β-alanine-controlled metabolic reprogramming
10.1016/j.celrep.2026.117208 · 2026 · External reference
10.1038/s41590-024-02014-5
10.1038/s41590-024-02014-5 · External reference
10.1038/s41556-025-01617-w
10.1038/s41556-025-01617-w · External reference
On the origin of metastases: Induction of pro-metastatic states after impending cell death via ER stress, reprogramming, and a cytokine storm
10.1016/j.celrep.2022.110490 · 2022 · External reference
10.1016/j.cels.2022.07.006
10.1016/j.cels.2022.07.006 · External reference
Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities
10.1016/j.xcrm.2024.101610 · 2024 · External reference
10.1038/s43018-020-0046-2
10.1038/s43018-020-0046-2 · External reference
10.1016/j.cell.2015.10.044
10.1016/j.cell.2015.10.044 · External reference
10.1038/s41571-025-01058-2
10.1038/s41571-025-01058-2 · External reference
10.1016/j.cell.2025.08.033
10.1016/j.cell.2025.08.033 · External reference
Twist1-induced invadopodia formation promotes tumor metastasis
10.1016/j.ccr.2011.01.036 · 2011 · External reference
10.1038/s41586-024-08575-7
10.1038/s41586-024-08575-7 · External reference
10.1158/1541-7786.mcr-24-0265
10.1158/1541-7786.mcr-24-0265 · External reference
Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer
10.1016/j.lungcan.2018.04.005 · 2018 · External reference
A newly developed anti-L1CAM monoclonal antibody targets small cell lung carcinoma cells
10.3390/ijms25168748 · 2024 · External reference
Integrated methylome analysis identifies an epigenetically silenced tumor suppressor RASA4 in small cell lung cancer
10.1038/s42003-025-09440-7 · 2025 · External reference
10.1158/2159-8290.cd-24-0296
10.1158/2159-8290.cd-24-0296 · External reference
MicroRNA-1 attenuates the growth and metastasis of small cell lung cancer through CXCR4/FOXM1/RRM2 axis
10.1186/s12943-022-01695-6 · 2023 · External reference
Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients
10.1016/j.celrep.2016.06.020 · 2016 · External reference
FOXA2 promotes metastatic competence in small cell lung cancer
10.1038/s41467-025-60141-5 · 2025 · External reference
10.1158/0008-5472.can-24-4245
10.1158/0008-5472.can-24-4245 · External reference
EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer
10.1073/pnas.2220276120 · 2023 · External reference
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells
10.1136/jitc-2023-007895 · 2024 · External reference
Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression
10.1038/s41467-025-67142-4 · 2025 · External reference
10.1016/j.immuni.2025.03.005
10.1016/j.immuni.2025.03.005 · External reference
Dopamine D2 receptor agonists abrogate neuroendocrine tumour angiogenesis to inhibit chemotherapy-refractory small cell lung cancer progression
10.1038/s41419-025-07693-y · 2025 · External reference
10.1016/j.jtho.2023.07.012
10.1016/j.jtho.2023.07.012 · External reference
10.1016/j.ccell.2025.07.008
10.1016/j.ccell.2025.07.008 · External reference
New insights into the correlations between circulating tumor cells and target organ metastasis
10.1038/s41392-023-01725-9 · 2023 · External reference
10.1038/s41568-024-00752-0
10.1038/s41568-024-00752-0 · External reference
Pre-metastatic niche: Formation, characteristics and therapeutic implication
10.1038/s41392-024-01937-7 · 2024 · External reference
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
10.1038/nature04186 · 2005 · External reference
10.1038/nm1101-1194
10.1038/nm1101-1194 · External reference
10.1158/2159-8290.cd-24-1847
10.1158/2159-8290.cd-24-1847 · External reference
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis
10.1038/s41586-023-06797-9 · 2023 · External reference
10.1016/j.immuni.2022.07.001
10.1016/j.immuni.2022.07.001 · External reference
10.1038/nature17038
10.1038/nature17038 · External reference
Macrophages in the premetastatic and metastatic niche: Key functions and therapeutic directions
10.1186/s12967-025-06556-6 · 2025 · External reference
10.1038/s41590-023-01475-4
10.1038/s41590-023-01475-4 · External reference
10.1038/s41586-023-06464-z
10.1038/s41586-023-06464-z · External reference
Mechanism insights and therapeutic intervention of tumor metastasis: Latest developments and perspectives
10.1038/s41392-024-01885-2 · 2024 · External reference
Mechanisms of small cell lung cancer metastasis
2020 · External reference
10.1016/j.cell.2025.08.013
10.1016/j.cell.2025.08.013 · External reference
Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer
10.1186/s13046-024-03266-7 · 2025 · External reference
10.1038/s41568-020-00320-2
10.1038/s41568-020-00320-2 · External reference
10.1016/j.cell.2026.04.017
10.1016/j.cell.2026.04.017 · External reference
10.1038/nature15376
10.1038/nature15376 · External reference
10.1038/s41586-025-09492-z
10.1038/s41586-025-09492-z · External reference
10.1038/s41586-025-09434-9
10.1038/s41586-025-09434-9 · External reference
10.1038/s41556-023-01241-6
10.1038/s41556-023-01241-6 · External reference
10.1158/2159-8290.cd-24-0134
10.1158/2159-8290.cd-24-0134 · External reference
10.1158/2159-8290.cd-21-0976
10.1158/2159-8290.cd-21-0976 · External reference
Comparative profiling of surgically resected primary tumors and their lymph node metastases in small-cell lung cancer
10.1016/j.esmoop.2025.104514 · 2025 · External reference
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models
10.1038/s41467-022-29517-9 · 2022 · External reference
10.1016/j.ccell.2021.09.008
10.1016/j.ccell.2021.09.008 · External reference
10.1016/j.cell.2023.03.003
10.1016/j.cell.2023.03.003 · External reference
10.1038/s41568-020-0263-0
10.1038/s41568-020-0263-0 · External reference
Primary tumor associated macrophages activate programs of invasion and dormancy in disseminating tumor cells
10.1038/s41467-022-28076-3 · 2022 · External reference
Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties
1985 · External reference
Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases
10.21037/tlcr.2019.11.30 · 2019 · External reference
10.1038/s41586-024-07177-7
10.1038/s41586-024-07177-7 · External reference
Epigenetic regulation of tumor immunity
10.1172/jci178540 · 2024 · External reference
10.1016/j.cell.2024.10.024
10.1016/j.cell.2024.10.024 · External reference
10.1016/j.cell.2025.06.021
10.1016/j.cell.2025.06.021 · External reference
Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers
10.1016/j.jtho.2021.08.763 · 2021 · External reference
10.1002/path.5922
10.1002/path.5922 · External reference
10.1164/rccm.202208-1471ed
10.1164/rccm.202208-1471ed · External reference
Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer
10.1016/j.celrep.2025.115603 · 2025 · External reference
10.1016/j.jtho.2020.09.009
10.1016/j.jtho.2020.09.009 · External reference
10.1101/gad.348295.121
10.1101/gad.348295.121 · External reference
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancer
10.1186/s12943-025-02514-4 · 2025 · External reference
10.1016/j.jtho.2020.05.008
10.1016/j.jtho.2020.05.008 · External reference
10.1038/s41556-023-01210-z
10.1038/s41556-023-01210-z · External reference
10.1016/j.ccell.2025.03.027
10.1016/j.ccell.2025.03.027 · External reference
Lamin A/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer
10.1073/pnas.2503387122 · 2025 · External reference
10.1158/1078-0432.ccr-22-1128
10.1158/1078-0432.ccr-22-1128 · External reference
Actin dysregulation induces neuroendocrine plasticity and immune evasion: A vulnerability of small cell lung cancer
10.1038/s41467-025-67078-9 · 2025 · External reference
Neuropeptide precursor VGF promotes neuroendocrine differentiation and cancer-associated fibroblast activation in small cell lung cancer
10.1158/0008-5472.can-25-0405 · 2025 · External reference
10.1267/ahc.22-00031
10.1267/ahc.22-00031 · External reference
10.1016/j.celrep.2016.06.081
10.1016/j.celrep.2016.06.081 · External reference
POU2AF2/C11orf53 functions as a coactivator of POU2F3 by maintaining chromatin accessibility and enhancer activity
10.1126/sciadv.abq2403 · 2022 · External reference
A SWI/SNF-dependent transcriptional regulation mediated by POU2AF2/C11orf53 at enhancer
10.1038/s41467-024-46492-5 · 2024 · External reference
10.1016/j.ccell.2024.06.012
10.1016/j.ccell.2024.06.012 · External reference
The rare YAP1 subtype of SCLC revisited in a biobank of 39 circulating tumor cell patient derived explant models: A brief report
10.1016/j.jtho.2020.07.008 · 2020 · External reference
10.1038/s43018-025-00945-y
10.1038/s43018-025-00945-y · External reference
10.1111/cas.13078
10.1111/cas.13078 · External reference
10.1158/1078-0432.ccr-23-2360
10.1158/1078-0432.ccr-23-2360 · External reference
YAP1 defines an emergent, plastic population of relapsed small cell lung cancer
10.1016/j.jtho.2026.103730 · 2026 · External reference
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
10.1016/j.ccell.2020.12.014 · 2021 · External reference
10.1016/j.ccell.2024.01.010
10.1016/j.ccell.2024.01.010 · External reference
Spatial proteomic profiling reveals conserved prognostic immune microenvironment features across molecular subtypes in small cell lung cancer
10.1016/j.phrs.2025.108048 · 2025 · External reference
10.1016/j.ccell.2020.05.001
10.1016/j.ccell.2020.05.001 · External reference
10.1158/1078-0432.ccr-24-0104
10.1158/1078-0432.ccr-24-0104 · External reference
The tumor immune microenvironment of SCLC is not associated with its molecular subtypes
10.1016/j.ejca.2024.115067 · 2024 · External reference
Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma
10.1126/sciadv.abp8674 · 2022 · External reference
10.1038/s41588-025-02343-7
10.1038/s41588-025-02343-7 · External reference
10.1038/s43018-019-0020-z
10.1038/s43018-019-0020-z · External reference
ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201
10.1016/j.ebiom.2024.105515 · 2025 · External reference
10.1016/j.ccell.2024.01.001
10.1016/j.ccell.2024.01.001 · External reference
Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer
10.1186/s12967-026-07940-6 · 2026 · External reference
Deep learning-based histomorphological subtyping and risk stratification of small cell lung cancer from hematoxylin and eosin-stained whole slide images
10.1186/s13073-025-01526-5 · 2025 · External reference
A whole-slide foundation model for digital pathology from real-world data
10.1038/s41586-024-07441-w · 2024 · External reference
10.1016/j.ccell.2025.01.012
10.1016/j.ccell.2025.01.012 · External reference
10.1038/s43018-025-00996-1
10.1038/s43018-025-00996-1 · External reference
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
10.1016/j.drup.2025.101215 · 2025 · External reference
10.1038/s41568-025-00803-0
10.1038/s41568-025-00803-0 · External reference
10.1038/s41571-020-0340-z
10.1038/s41571-020-0340-z · External reference
Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15
10.1038/s41388-024-03202-1 · 2024 · External reference
Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer
10.1038/s42003-021-01842-7 · 2021 · External reference
10.1038/s43018-023-00595-y
10.1038/s43018-023-00595-y · External reference
Ligand-independent EphA2 contributes to chemoresistance in small-cell lung cancer by enhancing PRMT1-mediated SOX2 methylation
10.1111/cas.15653 · 2022 · External reference
Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling
2020 · External reference
The impact of targeting TRAF2 and NCK-interacting protein kinase on antitumor effect and tumor immune environment in c-MYC-high SCLC
10.1016/j.jtho.2025.12.102 · 2025 · External reference
10.1158/0008-5472.can-21-3844
10.1158/0008-5472.can-21-3844 · External reference
10.1038/s41588-025-02204-3
10.1038/s41588-025-02204-3 · External reference
10.1038/s41588-025-02226-x
10.1038/s41588-025-02226-x · External reference
10.1016/j.cell.2025.04.012
10.1016/j.cell.2025.04.012 · External reference
Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC
10.1038/s41467-026-69262-x · 2026 · External reference
10.1158/2159-8290.cd-12-0112
10.1158/2159-8290.cd-12-0112 · External reference
Targeting DNA damage response pathways in cancer
10.1038/s41568-022-00535-5 · 2022 · External reference
HMGB1 promotes chemoresistance in small cell lung cancer by inducing PARP1-related nucleophagy
10.1016/j.jare.2023.12.020 · 2023 · External reference
Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis
10.1016/j.ccell.2017.01.006 · 2017 · External reference
Loss of the USP22 deubiquitylase confers resistance to chemotherapy in small cell lung cancer
10.1038/s41467-026-75117-2 · 2026 · External reference
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
10.1038/s41467-018-06162-9 · 2018 · External reference
KSR1 mediates small cell lung carcinoma tumor initiation and cisplatin resistance
10.1158/1541-7786.mcr-24-0652 · 2025 · External reference
Activation of PI3K/AKT pathway is a potential mechanism of treatment resistance in small cell lung cancer
10.1158/1078-0432.ccr-21-1943 · 2021 · External reference
10.1016/j.ccell.2018.06.012
10.1016/j.ccell.2018.06.012 · External reference
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer
10.1016/j.xcrm.2025.102194 · 2025 · External reference
S100A9 enhances tumor immune suppression and cancer cell survival in small cell lung cancer
10.1038/s41419-025-08102-0 · 2025 · External reference
Targeting PEA3 transcription factors to mitigate small cell lung cancer progression
10.1038/s41388-022-02558-6 · 2022 · External reference
Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis
10.1038/s41467-026-69899-8 · 2026 · External reference
Preclinical evidence that fibroblast growth factor receptor pathway inhibition by BGJ398 enhances small cell lung cancer response to chemotherapy
10.1097/cad.0000000000001683 · 2025 · External reference
10.1038/s41571-025-01059-1
10.1038/s41571-025-01059-1 · External reference
Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation
10.1016/j.jtho.2023.05.008 · 2023 · External reference
ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer
10.1038/s41467-025-66800-x · 2025 · External reference
10.1038/s41416-026-03390-5
10.1038/s41416-026-03390-5 · External reference
Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression
10.1016/j.canlet.2025.218160 · 2025 · External reference
10.1038/s41416-024-02821-5
10.1038/s41416-024-02821-5 · External reference
10.1038/s41590-024-01872-3
10.1038/s41590-024-01872-3 · External reference
10.1038/s41388-026-03798-6
10.1038/s41388-026-03798-6 · External reference
BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-cyclin D1/CDK4/6 axis
10.1038/s41392-026-02644-1 · 2026 · External reference
10.1016/j.ejca.2010.02.043
10.1016/j.ejca.2010.02.043 · External reference
10.1038/sj.onc.1204469
10.1038/sj.onc.1204469 · External reference
Bromodomain and hedgehog pathway targets in small cell lung cancer
10.1016/j.canlet.2015.12.001 · 2015 · External reference
10.1158/2159-8290.cd-20-0913
10.1158/2159-8290.cd-20-0913 · External reference
Multiscale information processing in the immune system
10.3389/fimmu.2025.1563992 · 2025 · External reference
Advances in molecular pathology and therapy of non-small cell lung cancer
10.1038/s41392-025-02243-6 · 2025 · External reference
10.1038/s41586-025-09539-1
10.1038/s41586-025-09539-1 · External reference
10.1038/s41590-025-02113-x
10.1038/s41590-025-02113-x · External reference
Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)
10.1200/jco.20.01055 · 2021 · External reference
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial
10.1016/s0140-6736(19)32222-6 · 2019 · External reference
10.1038/s41590-025-02176-w
10.1038/s41590-025-02176-w · External reference
10.1016/j.ccell.2026.02.008
10.1016/j.ccell.2026.02.008 · External reference
Cancer cells impair monocyte-mediated T cell stimulation to evade immunity
10.1038/s41586-024-08257-4 · 2024 · External reference
10.1038/s41590-025-02219-2
10.1038/s41590-025-02219-2 · External reference
10.1038/s41590-023-01443-y
10.1038/s41590-023-01443-y · External reference
10.1038/s41586-025-09188-4
10.1038/s41586-025-09188-4 · External reference
10.1038/s41568-022-00546-2
10.1038/s41568-022-00546-2 · External reference
Single-cell and spatial transcriptomics reveal that the CXCL12-CXCR4 axis drives the immune-desert phenotype in small cell lung cancer by recruiting immunosuppressive CXCR4+ neutrophils and S100A8+ monocytes
10.1136/jitc-2025-013867 · 2026 · External reference
10.1038/s41590-025-02233-4
10.1038/s41590-025-02233-4 · External reference
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
10.1126/sciimmunol.aay1863 · 2020 · External reference
Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity
10.1126/science.adr3026 · 2025 · External reference
10.1016/j.ccell.2025.03.021
10.1016/j.ccell.2025.03.021 · External reference
10.1016/j.ccell.2025.02.017
10.1016/j.ccell.2025.02.017 · External reference
10.1016/j.immuni.2025.06.006
10.1016/j.immuni.2025.06.006 · External reference
Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response
10.1126/sciimmunol.adg1487 · 2023 · External reference
10.1038/s41568-025-00832-9
10.1038/s41568-025-00832-9 · External reference
10.1016/j.immuni.2025.07.011
10.1016/j.immuni.2025.07.011 · External reference
10.1158/2159-8290.cd-25-1042
10.1158/2159-8290.cd-25-1042 · External reference
Intratumoral antigen signaling traps CD8+ T cells to confine exhaustion to the tumor site
10.1126/sciimmunol.ade2094 · 2024 · External reference
10.1016/j.ccell.2025.03.004
10.1016/j.ccell.2025.03.004 · External reference
10.1038/s41573-024-01017-z
10.1038/s41573-024-01017-z · External reference
10.1038/s41590-025-02144-4
10.1038/s41590-025-02144-4 · External reference
10.1038/s41568-024-00786-4
10.1038/s41568-024-00786-4 · External reference
10.1038/s41586-024-08439-0
10.1038/s41586-024-08439-0 · External reference
10.1158/2159-8290.cd-24-0199
10.1158/2159-8290.cd-24-0199 · External reference
In vivo functional screens reveal KEAP1 loss as a driver of chemoresistance in small cell lung cancer
10.1126/sciadv.adq7084 · 2025 · External reference
Increasing cisplatin exposure promotes small-cell lung cancer transformation after a shift from glucose metabolism to fatty acid metabolism
10.1007/s00432-025-06164-3 · 2025 · External reference
10.1038/s41568-025-00800-3
10.1038/s41568-025-00800-3 · External reference
10.1038/s41586-023-06483-w
10.1038/s41586-023-06483-w · External reference
10.1038/s41586-025-09202-9
10.1038/s41586-025-09202-9 · External reference
10.1016/j.immuni.2025.08.008
10.1016/j.immuni.2025.08.008 · External reference
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity
10.1016/j.ccell.2024.11.003 · 2024 · External reference
10.1038/s41590-025-02178-8
10.1038/s41590-025-02178-8 · External reference
10.1016/j.cmet.2016.08.011
10.1016/j.cmet.2016.08.011 · External reference
The LDH-H3K18La-Nur77 axis potentiates immune escape in small cell lung cancer
10.1002/advs.202413608 · 2025 · External reference
Hypoxia-inducible factor activity promotes antitumor effector function and tissue residency by CD8+ T cells
10.1172/jci143729 · 2021 · External reference
10.1016/j.immuni.2025.07.017
10.1016/j.immuni.2025.07.017 · External reference
Proteomic profiling reveals the significance of lipid metabolism in small cell lung cancer recurrence and metastasis
10.1186/s12967-024-05926-w · 2024 · External reference
10.1038/s41586-024-08258-3
10.1038/s41586-024-08258-3 · External reference
Dynamics of cachexia-associated inflammatory changes in the brain accompanying intra-abdominal fibrosarcoma growth in Wistar rats
10.1016/j.jneuroim.2023.578033 · 2023 · External reference
Unraveling the obesity paradox in small cell lung cancer immunotherapy: Unveiling prognostic insights through body composition analysis
10.3389/fimmu.2024.1439877 · 2024 · External reference
10.1038/s42255-025-01287-w
10.1038/s42255-025-01287-w · External reference
10.1038/s41592-025-02769-1
10.1038/s41592-025-02769-1 · External reference
10.1038/s42255-025-01338-2
10.1038/s42255-025-01338-2 · External reference
SCLC-CellMiner: A resource for small cell lung cancer cell line genomics and pharmacology based on genomic signatures
10.1016/j.celrep.2020.108296 · 2020 · External reference
10.1038/s43018-024-00854-6
10.1038/s43018-024-00854-6 · External reference
10.1038/s41590-023-01678-9
10.1038/s41590-023-01678-9 · External reference
State-of-the-art and future directions in structural proteomics
10.1016/j.mcpro.2025.101065 · 2025 · External reference
Spatial transcriptome-wide profiling of small cell lung cancer reveals intra-tumoral molecular and subtype heterogeneity
10.1002/advs.202402716 · 2024 · External reference
10.1038/s41586-025-08834-1
10.1038/s41586-025-08834-1 · External reference
10.1016/j.cell.2025.09.006
10.1016/j.cell.2025.09.006 · External reference
10.1016/j.cell.2024.01.042
10.1016/j.cell.2024.01.042 · External reference
Integrating multimodal cancer data using deep latent variable path modelling
10.1038/s42256-025-01052-4 · 2025 · External reference
10.1016/j.ccell.2025.06.005
10.1016/j.ccell.2025.06.005 · External reference
10.1038/s41568-024-00723-5
10.1038/s41568-024-00723-5 · External reference
10.1016/j.trecan.2024.07.008
10.1016/j.trecan.2024.07.008 · External reference
Insulinoma-associated protein 1 (INSM1) is a better marker for the diagnosis and prognosis estimation of small cell lung carcinoma than neuroendocrine phenotype markers such as chromogranin A, synaptophysin, and CD56
10.1097/pas.0000000000001444 · 2020 · External reference
10.1016/j.jtho.2022.06.004
10.1016/j.jtho.2022.06.004 · External reference
Paraneoplastic syndromes associated with small cell lung cancer
10.6004/jnccn.2006.0052 · 2006 · External reference
Malignancy detection rates of [68Ga]Ga-SSO120 PET/CT in patients with small cell lung cancer and large cell neuroendocrine lung cancer
10.2967/jnumed.125.270233 · 2026 · External reference
Positron emission tomography in limited-stage small-cell lung cancer: A prospective study
10.1200/jco.2004.11.089 · 2004 · External reference
Modern staging of small cell lung cancer
10.6004/jnccn.2013.0012 · 2013 · External reference
10.1038/s41571-025-00991-6
10.1038/s41571-025-00991-6 · External reference
10.1038/s43018-025-00917-2
10.1038/s43018-025-00917-2 · External reference
Artificial intelligence across the cancer care continuum
10.1002/cncr.70050 · 2025 · External reference
Surgery for early-stage small cell lung cancer
10.6004/jnccn.2011.0094 · 2011 · External reference
A meta-analysis of thoracic radiotherapy for small-cell lung cancer
10.1056/nejm199212033272302 · 1992 · External reference
Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): A randomised phase 3 study
10.1016/s1470-2045(13)70511-4 · 2013 · External reference
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): An open-label, phase 3, randomised, superiority trial
10.1016/s1470-2045(17)30318-2 · 2017 · External reference
Surgery after induced anti-PD-L1 therapy and chemotherapy for stage I–III small-cell lung cancer: A phase 2 trial (LungMate-005)
10.1038/s41421-025-00838-5 · 2025 · External reference
Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer
10.1200/jco.2015.63.8171 · 2016 · External reference
VP-16 and cisplatin as first-line therapy for small-cell lung cancer
10.1200/jco.1985.3.11.1471 · 1985 · External reference
Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer
10.1056/nejmoa2404873 · 2024 · External reference
Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer-final analysis from the phase II PACIFIC-6 trial
10.1016/j.esmoop.2025.105071 · 2025 · External reference
Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)
10.1093/annonc/mdq576 · 2011 · External reference
Durvalumab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: A prospective, single-arm, phase 2 clinical trial
10.1002/cncr.70351 · 2026 · External reference
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer
10.1200/jco.2004.01.178 · 2004 · External reference
Sintilimab plus concurrent chemoradiotherapy for treatment of locally advanced small cell lung cancer (SINCE-01): A phase II clinical trial
10.1038/s41392-026-02668-7 · 2026 · External reference
70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: Analysis of Cancer and Leukemia Group B study 39808
10.1016/j.ijrobp.2003.10.021 · 2004 · External reference
Chemoradiation ± atezolizumab in limited-stage small cell lung cancer: Results of NRG Oncology/Alliance LU005
10.1200/jco-25-01569 · 2026 · External reference
High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)/RTOG 0538
10.1200/jco.22.01359 · 2023 · External reference
Simultaneous integrated dose reduction radiation therapy versus conventional fractionated radiation therapy with chemotherapy for limited-stage small cell lung cancer in the modern treatment era: A phase 3, randomized clinical trial (SDR-RT trial)
10.1016/j.ijrobp.2025.09.058 · 2026 · External reference
Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer
10.1016/s0360-3016(02)04493-0 · 2003 · External reference
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: An open-label, randomised, phase 2 trial
10.1016/s1470-2045(20)30742-7 · 2021 · External reference
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: Usefulness of the individual patient data meta-analysis
10.1093/annonc/mdw263 · 2016 · External reference
10.1158/2159-8290.cd-23-1199
10.1158/2159-8290.cd-23-1199 · External reference
Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
10.1200/jco.1992.10.2.282 · 1992 · External reference
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
10.1056/nejmoa003034 · 2002 · External reference
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124
10.1200/jco.2008.20.1061 · 2009 · External reference
10.1200/jco.2005.04.8595
10.1200/jco.2005.04.8595 · External reference
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A randomized phase III trial
10.1200/jco.2007.15.7545 · 2008 · External reference
A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
10.1200/jco.1987.5.11.1731 · 1987 · External reference
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
10.1200/jco.1994.12.10.2022 · 1994 · External reference
Immunotherapeutic approaches for small-cell lung cancer
10.1038/s41571-019-0316-z · 2020 · External reference
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
10.1056/nejmoa1809064 · 2018 · External reference
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial
10.1016/s1470-2045(20)30539-8 · 2021 · External reference
Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: The ASTRUM-005 randomized clinical trial
10.1001/jama.2022.16464 · 2022 · External reference
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s1470-2045(22)00224-8 · 2022 · External reference
Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: The phase 3 EXTENTORCH randomized clinical trial
10.1001/jamaoncol.2024.5019 · 2025 · External reference
Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): A multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial
10.1016/j.jtho.2024.03.008 · 2024 · External reference
A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer
10.1038/s41392-024-02115-5 · 2025 · External reference
Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: A randomized phase 3 trial
10.1038/s41591-024-03132-1 · 2024 · External reference
Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161
10.1002/cncr.35938 · 2025 · External reference
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): A single-arm phase 2 trial
10.1016/s2213-2600(25)00240-1 · 2025 · External reference
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: A phase Ib/II trial
10.1038/s41392-024-01974-2 · 2024 · External reference
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: The GOIRC-01-2019 CeLEBrATE study
10.1136/jitc-2024-010694 · 2025 · External reference
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—A phase III trial of the Eastern Cooperative Oncology Group
10.1200/jco.2001.19.8.2114 · 2001 · External reference
The PESGA trial: A prospective, open-label, single-arm, phase II study to evaluate first line therapy for extensive-stage small cell lung cancer (ES-SCLC) patients, treated by induction carboplatin/etoposide/pembrolizumab followed by maintenance of pembrolizumab/sacituzumab govitecan
10.1016/j.cllc.2025.02.002 · 2025 · External reference
Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A multicenter, single-arm trial
10.1038/s41392-025-02153-7 · 2025 · External reference
Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)
10.1016/j.ejca.2025.116138 · 2025 · External reference
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): A multicentre, non-randomised, phase 1b study
10.1016/s1470-2045(25)00480-2 · 2025 · External reference
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): A randomised, multicentre, open-label, phase 3 trial
10.1016/s0140-6736(25)01011-6 · 2025 · External reference
Compliance and outcome of elderly patients treated in the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial
10.1016/j.jtho.2018.09.027 · 2019 · External reference
Role of chemoradiotherapy in elderly patients with limited-stage small-cell lung cancer
10.1200/jco.2015.62.4270 · 2015 · External reference
Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: That’s the question
10.21037/tlcr.2016.03.03 · 2016 · External reference
Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
10.4143/crt.2023.931 · 2024 · External reference
Consolidative thoracic radiotherapy with atezolizumab maintenance in extensive-stage small cell lung cancer: The phase 2 TREASURE randomized clinical trial (AIO-TRK-0320)
2026 · External reference
Prophylactic cranial irradiation in resected small cell lung cancer: A systematic review with meta-analysis
10.7150/jca.21465 · 2018 · External reference
Prophylactic cranial irradiation in extensive small-cell lung cancer
10.1056/nejmoa071780 · 2007 · External reference
“Hope” drives quality of life in patients with brain metastases, but, the “hope center” remains elusive: An analysis of NRG-CC003
10.1016/j.ijrobp.2025.06.3884 · 2025 · External reference
10.1200/jco-25-00221
10.1200/jco-25-00221 · External reference
10.1200/jco.19.02767
10.1200/jco.19.02767 · External reference
Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675)
10.1016/j.jtho.2020.12.024 · 2021 · External reference
Brain metastasis burden and management in patients with small cell lung cancer in Canada: A retrospective, population-based cohort study
10.1016/j.eclinm.2024.102871 · 2024 · External reference
Multicenter cohort study of original or substitute systemic therapy with or without brain radiotherapy for extensive-stage small cell lung cancer with brain-only progression after first-line treatment
10.1200/jco-25-02536 · 2026 · External reference
Low-dose radiation therapy concurrent with atezolizumab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer: 3-year follow-up of a multicenter, single-arm, phase 2 trial (MATCH)
10.1016/j.ijrobp.2025.06.3872 · 2025 · External reference
Lost at SCLC: A review of potential platinum sensitizers
10.1007/s10555-024-10207-5 · 2024 · External reference
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
10.6004/jnccn.2021.0058 · 2021 · External reference
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial
10.1016/s1470-2045(20)30461-7 · 2020 · External reference
10.1038/s43018-025-00992-5
10.1038/s43018-025-00992-5 · External reference
Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update
10.1200/jco.24.00553 · 2024 · External reference
Tarlatamab for patients with previously treated small-cell lung cancer
10.1056/nejmoa2307980 · 2023 · External reference
Tarlatamab in small-cell lung cancer after platinum-based chemotherapy
10.1056/nejmoa2502099 · 2025 · External reference
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: Analyses of the CASPIAN phase 3 study
10.1186/s12943-024-02014-x · 2024 · External reference
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial
10.1016/s1470-2045(20)30068-1 · 2020 · External reference
Lurbinectedin plus pembrolizumab in relapsed SCLC: The phase I/II LUPER study
10.1016/j.jtho.2025.02.005 · 2025 · External reference
Combination lurbinectedin and doxorubicin versus physician’s choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): A multicentre, randomised, open-label, phase 3 trial
10.1016/s2213-2600(22)00309-5 · 2023 · External reference
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
10.1200/jco.1999.17.2.658 · 1999 · External reference
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
10.1200/jco.2006.06.5821 · 2006 · External reference
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
10.1200/jco.2006.08.3998 · 2007 · External reference
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer
2006 · External reference
10.1200/jco.2018.77.7672
10.1200/jco.2018.77.7672 · External reference
Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer
10.1016/j.lungcan.2022.03.003 · 2022 · External reference
Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: Results from the CheckMate 032 randomized cohort
10.1016/j.jtho.2019.10.004 · 2020 · External reference
10.1200/jco.2017.72.5069
10.1200/jco.2017.72.5069 · External reference
Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies
10.1016/j.jtho.2019.12.109 · 2020 · External reference
Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451
10.1200/jco.20.02212 · 2021 · External reference
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
10.1016/j.annonc.2021.01.071 · 2021 · External reference
Unresolved reference
External reference
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: A randomized phase II study
10.1136/jitc-2020-001302 · 2020 · External reference
10.1016/j.jtho.2018.10.003
10.1016/j.jtho.2018.10.003 · External reference
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): A multicentre, open-label, phase 1/2 trial
10.1016/s1470-2045(16)30098-5 · 2016 · External reference
Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled phase 2 study
10.1038/s41416-021-01356-3 · 2021 · External reference
Sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-stage small cell lung cancer: A phase II clinical trial
10.1038/s41392-024-01957-3 · 2024 · External reference
Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03
10.1016/j.jtho.2024.12.028 · 2025 · External reference
Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: A phase II randomized controlled trial
10.1186/s12916-026-04835-7 · 2026 · External reference
Overall survival and quality-of-life superiority in modern phase 3 oncology trials: A meta-epidemiological analysis
10.1001/jamaoncol.2025.1002 · 2025 · External reference
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
10.1016/j.lungcan.2023.107418 · 2023 · External reference
Multi-omics reveals key molecular and cellular features of advanced small cell lung cancers associated with distinct therapeutic opportunities
10.1186/s13073-026-01624-y · 2026 · External reference
AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study
10.1016/j.canlet.2025.217872 · 2025 · External reference
Evaluating the prognostic impact of multiple 18FDG-PET imaging parameters in small-cell lung cancer: Insights from the long-term analysis of the CONVERT trial
10.1007/s00259-026-07812-7 · 2026 · External reference
Interpretable machine learning for survival prediction in small cell lung cancer patients with brain metastases: A population-based study with external validation
10.1177/10732748261419190 · 2026 · External reference
Single-cell spatial transcriptomics reveals tumor microenvironment heterogeneity in primary and lymph node-metastatic small cell lung cancer
10.1016/j.xcrm.2026.102713 · 2026 · External reference
Deep learning based histomorphological phenotyping and prognostic stratification for combined SCLC and LCNEC
2026 · External reference
MANIFEST: Multiomic platform for cancer immunotherapy
10.1158/2159-8290.cd-25-0099 · 2025 · External reference
AI-driven predictive biomarker discovery with contrastive learning to improve clinical trial outcomes
10.1016/j.ccell.2025.03.029 · 2025 · External reference
10.1016/j.cell.2025.05.027
10.1016/j.cell.2025.05.027 · External reference
10.1158/2159-8290.cd-24-1704
10.1158/2159-8290.cd-24-1704 · External reference
Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: An exploratory biomarker analysis of a phase II study
10.1038/s41392-025-02252-5 · 2025 · External reference
Targeting macrophage-driven NK cell immunosuppression to improve cancer immunotherapy
10.1136/jitc-2026-014840 · 2026 · External reference
10.1016/j.ccell.2018.04.001
10.1016/j.ccell.2018.04.001 · External reference
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
10.1186/s40425-019-0821-8 · 2019 · External reference
Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples
10.1016/j.lungcan.2026.109418 · 2026 · External reference
Correction: FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis
10.1038/s41388-021-02044-5 · 2021 · External reference
Predicting resistance to chemotherapy using chromosomal instability signatures
10.1038/s41588-025-02233-y · 2025 · External reference
10.1016/j.jtho.2016.09.002
10.1016/j.jtho.2016.09.002 · External reference
Clinical and prognostic implications of CD47 and PD-L1 expression in surgically resected small-cell lung cancer
10.1016/j.esmoop.2022.100631 · 2022 · External reference
10.1158/2159-8290.cd-25-1483
10.1158/2159-8290.cd-25-1483 · External reference
Circulating tumor DNA refines consolidation immunotherapy for limited-stage small cell lung cancer patients
10.1038/s41392-025-02445-y · 2025 · External reference
Integrated circulating tumor DNA-based prognostic algorithm for limited stage small-cell lung cancer under definitive chemoradiotherapy and utility in consolidation immunotherapy benefit prediction
10.1186/s12964-025-02462-y · 2025 · External reference
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer
10.1016/j.lungcan.2025.108723 · 2025 · External reference
Profiling the tumor-resident microbiota in small cell lung cancer and its influence on clinical outcomes
10.1186/s12967-026-08109-x · 2026 · External reference
Locus-specific human endogenous retrovirus ERVK18 expression indicates an inflamed microenvironment and favorable immunotherapy outcome in small cell lung cancer
10.1158/1078-0432.ccr-25-3302 · 2026 · External reference
Dasatinib remodels the tumor microenvironment and sensitizes small cell lung cancer to immunotherapy
10.1158/0008-5472.can-24-2772 · 2025 · External reference
IFITM3 enhances immunosensitivity via MHC-I regulation and is associated with the efficacy of anti-PD-1/-L1 therapy in SCLC
10.1186/s12943-025-02383-x · 2025 · External reference
The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
10.1038/s41416-020-01202-y · 2021 · External reference
PARP inhibitors as therapy for small cell lung carcinoma: A systematic review and meta-analysis of clinical trials
2024 · External reference
Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study
10.1200/jco.20.00793 · 2020 · External reference
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
10.1016/j.esmoop.2022.100408 · 2022 · External reference
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial
10.1200/jco.2010.29.3423 · 2011 · External reference
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501
10.1200/jco.2009.23.7545 · 2009 · External reference
Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial†
10.1093/annonc/mdv065 · 2015 · External reference
Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients with SLFN11 positive extensive-stage SCLC: S1929
10.1016/j.jtho.2024.10.021 · 2025 · External reference
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival analysis of the phase III TROPION-Breast01 study
10.1016/j.annonc.2025.12.017 · 2026 · External reference
10.1158/2159-8290.cd-24-0827
10.1158/2159-8290.cd-24-0827 · External reference
Unresolved reference
External reference
Dose selection of novel anticancer drugs: Exposing the gap between selected and required doses
10.1016/s1470-2045(24)00134-7 · 2024 · External reference
10.1016/j.jtho.2021.02.009
10.1016/j.jtho.2021.02.009 · External reference
10.1016/j.jtho.2021.03.012
10.1016/j.jtho.2021.03.012 · External reference
Artificial intelligence and machine learning innovations to improve design and representativeness in oncology clinical trials
10.1200/edbk-25-473590 · 2025 · External reference
10.2174/0113816128308066240529121148
10.2174/0113816128308066240529121148 · External reference
Inductive transfer learning for molecular activity prediction: Next-gen QSAR models with MolPMoFiT
2020 · External reference
Discovery of novel aldose reductase inhibitors via the integration of ligand-based and structure-based virtual screening with experimental validation
10.1021/acsomega.4c00820 · 2024 · External reference
10.1021/acs.chemrev.5c00461
10.1021/acs.chemrev.5c00461 · External reference
Current strategies to address data scarcity in artificial intelligence-based drug discovery: A comprehensive review
10.1016/j.compbiomed.2024.108734 · 2024 · External reference
DynamicBind: Predicting ligand-specific protein-ligand complex structure with a deep equivariant generative model
10.1038/s41467-024-45461-2 · 2024 · External reference
10.1038/s41586-021-03819-2
10.1038/s41586-021-03819-2 · External reference
10.1126/science.abj8754
10.1126/science.abj8754 · External reference
10.1038/s41586-024-07487-w
10.1038/s41586-024-07487-w · External reference
De novo design of epitope-specific antibodies via a structure-driven computational workflow
10.1038/s41467-025-67361-9 · 2025 · External reference
AttABseq: An attention-based deep learning prediction method for antigen-antibody binding affinity changes based on protein sequences. Briefings in
2024 · External reference
10.1038/s41586-023-06415-8
10.1038/s41586-023-06415-8 · External reference
Artificial intelligence-driven computational methods for antibody design and optimization
10.1080/19420862.2025.2528902 · 2025 · External reference
10.1021/acs.jcim.3c01753
10.1021/acs.jcim.3c01753 · External reference
10.2174/1381612829666230428110542
10.2174/1381612829666230428110542 · External reference
Evaluating ligand docking methods for drugging protein-protein interfaces: Insights from AlphaFold2 and molecular dynamics refinement
2025 · External reference
10.1021/acs.jcim.3c00519
10.1021/acs.jcim.3c00519 · External reference
A relative binding free energy framework for structurally dissimilar molecules
10.1021/acs.jcim.5c02204 · 2026 · External reference
DeePMD-kit v2: A software package for deep potential models
10.1063/5.0155600 · 2023 · External reference
ProfhEX: Empowering early drug discovery with machine learning-based target profiling and liability prediction
10.1021/acs.jcim.5c02250 · 2025 · External reference
MGraphDTA: Deep multiscale graph neural network for explainable drug-target binding affinity prediction
10.1039/d1sc05180f · 2022 · External reference
Token-Mol 1.0: Tokenized drug design with large language models
10.1038/s41467-025-59628-y · 2025 · External reference
ADMET-AI enables interpretable predictions of drug-induced cardiotoxicity
10.1161/circulationaha.124.070413 · 2025 · External reference
Deep-PK: Deep learning for small molecule pharmacokinetic and toxicity prediction
10.1093/nar/gkae254 · 2024 · External reference
10.1038/s41557-022-01055-3
10.1038/s41557-022-01055-3 · External reference
10.1038/s41586-024-08393-x
10.1038/s41586-024-08393-x · External reference
Machine learning models for predicting monoclonal antibody biophysical properties from molecular dynamics simulations and deep learning-based surface descriptors
10.1021/acs.molpharmaceut.4c00804 · 2025 · External reference
10.1093/annonc/mdz278
10.1093/annonc/mdz278 · External reference
10.1158/2159-8290.cd-24-1421
10.1158/2159-8290.cd-24-1421 · External reference
NHWD-870 suppresses tumor proliferation via the BRD4/STRADA/CCND1 axis in small cell lung cancer
10.1016/j.lungcan.2025.108841 · 2025 · External reference
MYC family amplification dictates sensitivity to BET bromodomain protein inhibitor mivebresib (ABBV075) in small-cell lung cancer
10.1158/1541-7786.mcr-23-0599 · 2024 · External reference
First-in-human study of AZD5153, A small-molecule inhibitor of bromodomain protein 4, in patients with relapsed/refractory malignant solid tumors and lymphoma
10.1158/1535-7163.mct-23-0065 · 2023 · External reference
10.1158/1541-7786.mcr-23-0405
10.1158/1541-7786.mcr-23-0405 · External reference
mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
10.1172/jci.insight.156657 · 2023 · External reference
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
10.1016/j.celrep.2022.110814 · 2022 · External reference
Polo-like kinase 1 inhibitors demonstrate in vitro and in vivo efficacy in preclinical models of small cell lung cancer
10.3390/cancers17030446 · 2025 · External reference
10.1158/2159-8290.cd-18-0389
10.1158/2159-8290.cd-18-0389 · External reference
CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer
10.21037/tlcr-24-33 · 2024 · External reference
10.1016/j.ccell.2019.11.003
10.1016/j.ccell.2019.11.003 · External reference
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors
10.1038/s41586-025-09433-w · 2025 · External reference
10.1158/1535-7163.mct-23-0602
10.1158/1535-7163.mct-23-0602 · External reference
Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: Primary and correlative biomarker analyses
10.1016/j.jtho.2019.10.013 · 2020 · External reference
10.1158/1078-0432.ccr-23-0375
10.1158/1078-0432.ccr-23-0375 · External reference
10.1158/0008-5472.can-21-2964
10.1158/0008-5472.can-21-2964 · External reference
Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
10.1038/s41420-022-01296-8 · 2023 · External reference
Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation
10.1016/j.taap.2025.117375 · 2025 · External reference
ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer
10.15252/emmm.202217313 · 2023 · External reference
Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: A randomized, double-blind, phase 3 study
10.1016/j.jtho.2021.04.001 · 2021 · External reference
10.1158/1078-0432.ccr-24-4342
10.1158/1078-0432.ccr-24-4342 · External reference
10.1158/2159-8290.cd-23-0486
10.1158/2159-8290.cd-23-0486 · External reference
10.1016/j.jtho.2022.05.014
10.1016/j.jtho.2022.05.014 · External reference
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition
10.1126/scisignal.aau2922 · 2019 · External reference
10.1016/j.ccell.2019.08.008
10.1016/j.ccell.2019.08.008 · External reference
Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1
10.1038/s41467-022-31998-7 · 2022 · External reference
HDAC6 orchestrates metastatic and immunosuppressive programs in small cell lung cancer through S100A2-TGF-β/SMAD and CSF1R signaling
10.1186/s12943-025-02552-y · 2026 · External reference
Jumonji histone demethylases are therapeutic targets in small cell lung cancer
10.1038/s41388-024-03125-x · 2024 · External reference
TRIM21-mediated ubiquitination of PARP1 regulated by the PI3K/AKT-STAT5A axis suppresses small cell lung cancer
10.1038/s41467-026-73271-1 · 2026 · External reference
10.1158/2159-8290.cd-18-1020
10.1158/2159-8290.cd-18-1020 · External reference
Rationale and design of the phase 3 KEYLYNK-013 study of pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for limited-stage small-cell lung cancer
10.1016/j.cllc.2022.04.005 · 2022 · External reference
LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC
10.1038/s41467-026-70984-1 · 2026 · External reference
Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1
10.1016/j.xcrm.2023.101282 · 2023 · External reference
Small cell lung cancer: Novel treatments beyond immunotherapy
10.1016/j.semcancer.2022.05.004 · 2022 · External reference
Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: An open-label, single-arm, multicenter, multi-cohort phase II trial
10.1007/s00262-024-03932-x · 2025 · External reference
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): A multicenter, randomized, phase II trial and biomarker analysis
10.1038/s41467-026-73562-7 · 2026 · External reference
10.1038/s41568-025-00817-8
10.1038/s41568-025-00817-8 · External reference
Beyond rule of five and PROTACs in modern drug discovery: Polarity reducers, chameleonicity, and the evolving physicochemical landscape
10.1021/acs.jmedchem.3c02332 · 2024 · External reference
Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors
10.1093/oncolo/oyag133 · 2026 · External reference
10.1038/s41573-025-01262-w
10.1038/s41573-025-01262-w · External reference
10.1038/s41573-023-00833-z
10.1038/s41573-023-00833-z · External reference
10.1016/j.immuni.2025.06.001
10.1016/j.immuni.2025.06.001 · External reference
SKYSCRAPER-02: Tiragolumab in combination with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung cancer
10.1200/jco.23.01363 · 2024 · External reference
First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors
10.1136/jitc-2025-012729 · 2026 · External reference
10.1158/2159-8290.cd-25-1454
10.1158/2159-8290.cd-25-1454 · External reference
10.1038/s41573-024-00896-6
10.1038/s41573-024-00896-6 · External reference
Somatostatin receptor 2 targeting peptide modifications for peptide-drug conjugate treatment of small cell lung cancer
10.1038/s41401-025-01584-w · 2025 · External reference
10.1038/s41571-024-00905-y
10.1038/s41571-024-00905-y · External reference
10.1158/2326-6066.cir-23-0638
10.1158/2326-6066.cir-23-0638 · External reference
10.1016/j.cell.2025.09.001
10.1016/j.cell.2025.09.001 · External reference
Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes
10.1158/1078-0432.ccr-24-3981 · 2025 · External reference
Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial
10.1200/jco-25-02142 · 2026 · External reference
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial
10.1016/j.ccell.2026.02.006 · 2026 · External reference
A phase I first-in-human study of ABBV-011, a seizure-related homolog protein 6-targeting antibody-drug conjugate, in patients with small cell lung cancer
10.1158/1078-0432.ccr-24-1547 · 2024 · External reference
Izalontamab brengitecan (iza-bren), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate in extensive-stage small cell lung cancer: Results from a phase Ib study
2026 · External reference
Targeting the somatostatin receptor 2 with the miniaturized drug conjugate, PEN-221: A potent and novel therapeutic for the treatment of small cell lung cancer
10.1158/1535-7163.mct-19-0022 · 2019 · External reference
10.1038/s41586-023-05707-3
10.1038/s41586-023-05707-3 · External reference
10.1158/1078-0432.ccr-22-2293
10.1158/1078-0432.ccr-22-2293 · External reference
10.1002/jcph.2346
10.1002/jcph.2346 · External reference
10.1016/j.ccell.2025.01.013
10.1016/j.ccell.2025.01.013 · External reference
Parallel 4-1BB signaling in dual DLL3/CD56-targeting CAR-T cells triggers adaptive proliferation and functional persistence to eradicate small cell lung cancer
10.1158/0008-5472.can-25-5261 · 2026 · External reference
Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer
10.1136/jitc-2021-003897 · 2022 · External reference
10.1158/2767-9764.crc-23-0259
10.1158/2767-9764.crc-23-0259 · External reference
Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer
10.1016/j.canlet.2022.215697 · 2022 · External reference
Targeting CD276 with adapter-CAR T-cells provides a novel therapeutic strategy in small cell lung cancer and prevents CD276-dependent fratricide
10.1186/s13045-025-01729-8 · 2025 · External reference
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
10.1136/jitc-2024-010073 · 2025 · External reference
Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
10.1136/jitc-2020-000785 · 2020 · External reference
10.1016/j.cell.2025.03.017
10.1016/j.cell.2025.03.017 · External reference
Trained immunity-primed DLL3-targeted CAR macrophages for the eradication of small cell lung cancer
2026 · External reference
New developments in immunotherapy for SCLC
10.1136/jitc-2024-009667 · 2025 · External reference
CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo
10.1002/jlb.5ma0122-467r · 2022 · External reference
Oncolytic virotherapy: Basic principles, recent advances and future directions
10.1038/s41392-023-01407-6 · 2023 · External reference
10.1016/j.ccell.2025.03.010
10.1016/j.ccell.2025.03.010 · External reference
